Omada Health, Inc. (OMDA) Earnings Call Transcripts

Omada Health, Inc.'s Latest Earnings Call - June 10, 2026

In the Q1 2026 earnings call for Omada Health, Inc., the company reported a revenue of $78 million, reflecting a 43% year-over-year growth, and achieved adjusted EBITDA positivity in a typically cost-heavy quarter. Management emphasized their successful execution of commitments made during the IPO and highlighted the strong demand for their chronic care solutions. Looking ahead, Omada is optimistic about continued growth, particularly through the integration of GLP-1 medications into their offerings, although they maintained a cautious approach to guidance, reflecting their conservative outlook on new account conversions and member growth.

Reported metrics

Guidance from management

Management maintained a conservative approach to guidance, emphasizing the need for a measured strategy in new account conversions and member growth. They indicated that growth from new channels would be gradual and dependent on the sales cycle.

What management said

I think 1 -- just from an economic standpoint. On the R&D side, we want to spin up a new car on our existing tech stack. We approach that with like modularity and flexibility migrate new GLP-1 product just a couple of months tech stack. So we don't need to go back and deploy tens of million or to reinvest to stand that up. And so that's going to continue to benefit us from an operating leverage perspective as well.

Yes, that's right. And ending Q1 numbers was just north of 1 million. So it gives you a general sense. Because in any given account, there's still going to be the minority on a GLP, we expect that those proportions to continue.

What analysts pressed on

Analysts expressed concerns regarding the sustainability of growth driven by GLP-1 medications and the potential dilution of revenue per member as engagement levels fluctuate. There were questions about how new account acquisitions would impact overall revenue growth.

Main topics on the call

• Revenue Growth Acceleration — Omada reported a revenue of $78 million for Q1 2026, representing a 43% increase year-over-year. CEO Sean Duffy stated, "I think we've come ahead of schedule in many areas," indicating strong operational performance.
• Positive Adjusted EBITDA — The company achieved adjusted EBITDA positivity in Q1, which is significant given it is typically the most cost-heavy quarter of the year. This milestone reflects operational efficiency and effective cost management.
• GLP-1 Integration — Management highlighted the launch of their GLP-1 Care Track, which aims to enhance patient outcomes and reduce costs for employers. Duffy noted, "We developed the first version of our Care Track... optimizing for on-ther...
• Sustainable Business Model — Omada's revenue model is based on a monthly fee structure that aligns with customer engagement. Duffy mentioned, "When someone times up, we start to charge," emphasizing the model's durability and customer alignment.

Read the full Omada Health, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 24 Omada Health, Inc. earnings call transcripts on record, spanning November 30, 2022 to June 10, 2026. Based on this history, Omada Health, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

OMDA

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

24

First call

November 30, 2022

Most recent

June 10, 2026

Reporting cadence

quarterly